PARP2 (Poly [ADP-ribose] polymerase 2) variants and mutations
PARP2 (also known as Poly [ADP-ribose] polymerase 2) is a human protein-coding gene encoding a poly [ADP-ribose] polymerase 2 protein. It cooperates with PARP1 in sensing DNA damage and promoting poly(ADP-ribose)-dependent repair, particularly at single-strand breaks. Its activity contributes to the response to PARP inhibitors and to DNA-repair redundancy in cancer cells. This analysis covers 352 PARP2 variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes ovarian cancer, neoplasm, and breast cancer. Example PARP2 variants include A2T, A2P, and A2G.
Variant analysis overview
- Gene: PARP2
- Protein: Poly [ADP-ribose] polymerase 2
- UniProt accession: Q9UGN5
- Organism: Homo sapiens
- Variants analyzed: 352
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 97 unspecified-consequence records; 20 frameshift variants; 181 missense variants; 41 synonymous variants; 2 in-frame insertions; 6 stop-gained variants; 4 splice-region variants; 1 in-frame deletions
- Prediction scores: 279 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: ovarian cancer, neoplasm, breast cancer, fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma, prostate cancer, breast neoplasm, ovarian neoplasm, peritoneum cancer, fallopian tube carcinoma, peritoneal neoplasm.
Protein structure and variant hotspots
- Protein features: 3 domains; 4 binding sites; 4 post-translational modification sites.
- Structural context: 91 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PARP2 variants
Examples include A2T, A2P, A2G, A2V, A2E, A2A, A3S, A3T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), rs1206277684, gnomAD 14-20343645-G-A, REVEL 0.15, CADD 24.70
- A2P (p.Ala2Pro), gnomAD 14-20343645-G-C, REVEL 0.13, CADD 24.90
- A2G (p.Ala2Gly), gnomAD 14-20343646-C-G, REVEL 0.11, CADD 27.20
- A2V (p.Ala2Val), gnomAD 14-20343646-C-T, REVEL 0.10, CADD 23.30
- A2E (p.Ala2Glu), gnomAD 14-20343646-C-A, REVEL 0.10, CADD 24.10
- A2A (p.Ala2Ala), rs1307860934, gnomAD 14-20343647-G-A, CADD 3.77
- A3S (p.Ala3Ser), gnomAD 14-20343648-G-T, REVEL 0.03, CADD 8.10
- A3T (p.Ala3Thr), gnomAD 14-20343648-G-A, REVEL 0.03, CADD 9.98
- A3V (p.Ala3Val), gnomAD 14-20343649-C-T, REVEL 0.04, CADD 21.60
- A3E (p.Ala3Glu), gnomAD 14-20343649-C-A, REVEL 0.07, CADD 19.90
- A3A (p.Ala3Ala), gnomAD 14-20343650-G-C, CADD 1.67
- R4G (p.Arg4Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R4R (p.Arg4Arg), rs1883593018, gnomAD 14-20343651-C-A, CADD 9.98
- R4L (p.Arg4Leu), gnomAD 14-20343652-G-T, REVEL 0.15, CADD 17.50
- R4Q (p.Arg4Gln), rs1883593229, gnomAD 14-20343652-G-A, REVEL 0.14, CADD 17.10
- R5W (p.Arg5Trp), rs1448690733, gnomAD 14-20343654-C-T, REVEL 0.12, CADD 23.30
- R5Q (p.Arg5Gln), rs750367087, gnomAD 14-20343655-G-A, REVEL 0.17, CADD 22.80
- R6P (p.Arg6Pro), rs762731089, ClinGen CA389115855, ClinVar RCV004145999, AlphaMissense 0.25, MetaLR 0.03, Uncertain significance, not specified
- R6G (p.Arg6Gly), rs1319824725, gnomAD 14-20343644-G-GGC, CADD 25.40
- R6R (p.Arg6Arg), gnomAD 14-20343657-C-A, CADD 12.70
- R6* (p.Arg6Ter), rs898757585, gnomAD 14-20343657-C-T, CADD 36.00
- R6Q (p.Arg6Gln), rs762731089, gnomAD 14-20343658-G-A, REVEL 0.06, AlphaMissense 0.25
- R7E (p.Arg7Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R7Q (p.Arg7Gln), rs754797447, NCI-TCGA Cosmic COSV5164, cosmic curated COSV51640, NCI-TCGA Cosmic COSV9916, REVEL 0.05, CADD 15.90, Variant assessed as somatic; moderate impact.
- p.Arg7dup, gnomAD 14-20343649-C-CGC, CADD 14.20
- R7G (p.Arg7Gly), rs566133010, gnomAD 14-20343660-C-G, REVEL 0.02, CADD 17.00
- R7W (p.Arg7Trp), rs566133010, gnomAD 14-20343660-C-T, REVEL 0.11, CADD 20.60
- R7L (p.Arg7Leu), gnomAD 14-20343661-G-T, REVEL 0.04, CADD 16.60
- R7P (p.Arg7Pro), rs754797447, gnomAD 14-20343661-G-C, REVEL 0.08, CADD 17.80
- R7R (p.Arg7Arg), rs752976873, gnomAD 14-20343662-G-A, CADD 8.46
- S8G (p.Ser8Gly), gnomAD 14-20343663-A-G, REVEL 0.01, CADD 13.30
- S8N (p.Ser8Asn), rs756215931, gnomAD 14-20343664-G-A, REVEL 0.06, CADD 12.80
- S8R (p.Ser8Arg), gnomAD 14-20343665-C-G, REVEL 0.03, CADD 3.58
- S8S (p.Ser8Ser), rs1264473453, gnomAD 14-20343665-C-T, CADD 5.54
- T9S (p.Thr9Ser), rs747087413, gnomAD 14-20343649-C-CGC, CADD 22.60
- T9R (p.Thr9Arg), rs1566415056, gnomAD 14-20343664-GCA-G, CADD 13.30
- T9A (p.Thr9Ala), rs1883595323, gnomAD 14-20343666-A-G, REVEL 0.02, CADD 1.98
- T9I (p.Thr9Ile), rs777650803, gnomAD 14-20343667-C-T, REVEL 0.04, CADD 12.70
- T9N (p.Thr9Asn), rs777650803, gnomAD 14-20343667-C-A, REVEL 0.04, CADD 11.00
- T9T (p.Thr9Thr), rs749403962, gnomAD 14-20343668-C-A, CADD 2.84
- G10A (p.Gly10Ala), rs1461324778, gnomAD 14-20343666-AC-A, CADD 22.30
- G10C (p.Gly10Cys), gnomAD 14-20343669-G-T, REVEL 0.09, CADD 0.72
- G10S (p.Gly10Ser), rs1034133955, gnomAD 14-20343669-G-A, REVEL 0.02, CADD 0.42
- G10G (p.Gly10Gly), rs1883596370, gnomAD 14-20343671-C-G, CADD 12.10
- G11S (p.Gly11Ser), gnomAD 14-20343672-G-A, REVEL 0.01, CADD 1.25
- G11R (p.Gly11Arg), gnomAD 14-20343672-G-C, REVEL 0.05, CADD 1.81
- G11C (p.Gly11Cys), gnomAD 14-20343672-G-T, REVEL 0.14, CADD 6.70
- G11G (p.Gly11Gly), rs771296313, gnomAD 14-20343674-C-T, CADD 7.22
- G12D (p.Gly12Asp), gnomAD 14-20343650-G-GCG, CADD 19.80
- G12R (p.Gly12Arg), rs779597599, gnomAD 14-20343675-G-C, REVEL 0.04, CADD 0.11
- G12S (p.Gly12Ser), rs779597599, gnomAD 14-20343675-G-A, REVEL 0.03, CADD 0.13
- G12C (p.Gly12Cys), rs779597599, gnomAD 14-20343675-G-T, REVEL 0.05, CADD 0.10
- G12V (p.Gly12Val), rs746201116, gnomAD 14-20343676-G-T, REVEL 0.02, CADD 12.20
- G12G (p.Gly12Gly), rs1301912906, gnomAD 14-20343677-C-T, CADD 13.30
- R13D (p.Arg13Asp), rs1555315933, gnomAD 14-20343649-C-CGC, CADD 22.60
- R13R (p.Arg13Arg), gnomAD 14-20343678-A-C, CADD 2.64
- R13G (p.Arg13Gly), rs1157146586, gnomAD 14-20343678-A-G, REVEL 0.04, CADD 1.11
- A14V (p.Ala14Val), rs1415110483, NCI-TCGA Cosmic COSV5163, cosmic curated COSV51638, gnomAD rs1415110483, AlphaMissense 0.12, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- A14T (p.Ala14Thr), rs1347928953, gnomAD 14-20343681-G-A, REVEL 0.00, CADD 1.82
- A14S (p.Ala14Ser), gnomAD 14-20343681-G-T, REVEL 0.01, CADD 1.46
- A14G (p.Ala14Gly), rs1415110483, gnomAD 14-20343682-C-G, REVEL 0.02, AlphaMissense 0.12
- A14A (p.Ala14Ala), gnomAD 14-20343683-G-C, CADD 6.48
- R15G (p.Arg15Gly), rs200603922, gnomAD 14-20343684-A-G, REVEL 0.01, CADD 16.50
- R15K (p.Arg15Lys), rs1444241687, gnomAD 14-20343685-G-A, REVEL 0.03, CADD 13.20
- R15R (p.Arg15Arg), rs776404988, gnomAD 14-20343686-A-G, CADD 24.10
- A16T (p.Ala16Thr), rs1349582575, gnomAD 14-20343687-G-A, REVEL 0.14, CADD 33.00
- A16V (p.Ala16Val), gnomAD 14-20344932-C-T, REVEL 0.04, CADD 12.40
- A16A (p.Ala16Ala), gnomAD 14-20344933-A-G, CADD 10.60
- L17V (p.Leu17Val), gnomAD 14-20344934-T-G, REVEL 0.03, CADD 7.60
- N18H (p.Asn18His), gnomAD 14-20344937-A-C, REVEL 0.04, CADD 13.20
- S20I (p.Ser20Ile), gnomAD 14-20344944-G-T, REVEL 0.03, CADD 9.54
- K21Q (p.Lys21Gln), rs1299062113, gnomAD 14-20344946-A-C, REVEL 0.01, CADD 2.32
- K21K (p.Lys21Lys), rs1342110276, gnomAD 14-20344948-A-G, CADD 3.36
- R22T (p.Arg22Thr), rs370855552, gnomAD 14-20344950-G-C, REVEL 0.03, CADD 6.11
- V23I (p.Val23Ile), gnomAD 14-20344952-G-A, REVEL 0.10, CADD 12.90
- N24* (p.Asn24Ter), rs1357410876, gnomAD 14-20344954-TAA-T, CADD 22.40
- N24K (p.Asn24Lys), rs766131038, gnomAD 14-20344955-AAT-A, CADD 22.50
- N25del (p.Asn25del), rs762092776, gnomAD 14-20344953-TTAA-, CADD 12.20
- G26A (p.Gly26Ala), gnomAD 14-20344960-TG-T, CADD 22.90
- G26S (p.Gly26Ser), gnomAD 14-20344961-G-A, REVEL 0.09, CADD 15.90
- G26D (p.Gly26Asp), rs1381122398, gnomAD 14-20344962-G-A, REVEL 0.06, AlphaMissense 0.69
- N27W (p.Asn27Trp), rs774266943, gnomAD 14-20344958-A-AAT, CADD 22.70
- N27T (p.Asn27Thr), gnomAD 14-20344965-A-C, REVEL 0.04, AlphaMissense 0.62
- T28M (p.Thr28Met), NCI-TCGA TCGA novel, gnomAD rs1883656573, REVEL 0.03, CADD 7.50, Variant assessed as somatic; moderate impact.
- T28A (p.Thr28Ala), gnomAD 14-20344967-A-G, REVEL 0.01, CADD 0.41
- T28T (p.Thr28Thr), rs559843221, gnomAD 14-20344969-G-A, CADD 0.44
- A29T (p.Ala29Thr), rs1189262397, gnomAD 14-20344970-G-A, REVEL 0.07, CADD 4.77
- P30S (p.Pro30Ser), NCI-TCGA Cosmic COSV5164, cosmic curated COSV51641, Variant assessed as somatic; moderate impact.
- P30L (p.Pro30Leu), gnomAD 14-20344974-C-T, REVEL 0.05, CADD 7.31
- P30P (p.Pro30Pro), rs951988086, gnomAD 14-20344975-A-T, CADD 6.53
- E31D (p.Glu31Asp), rs1420227286, gnomAD 14-20344978-A-C, REVEL 0.03, CADD 9.90
- S33T (p.Ser33Thr), gnomAD 14-20344982-T-A, REVEL 0.02, CADD 0.02
- S33A (p.Ser33Ala), rs1883657438, gnomAD 14-20344982-T-G, REVEL 0.03, CADD 0.01
- S33P (p.Ser33Pro), gnomAD 14-20344982-T-C, REVEL 0.02, CADD 0.18
- S33F (p.Ser33Phe), rs1247450894, gnomAD 14-20344983-C-T, REVEL 0.04, CADD 10.30
- S34Y (p.Ser34Tyr), gnomAD 14-20344986-C-A, REVEL 0.09, CADD 16.30
- P35S (p.Pro35Ser), gnomAD 14-20344988-C-T, REVEL 0.05, CADD 12.70
- P35L (p.Pro35Leu), gnomAD 14-20344989-C-T, REVEL 0.17, AlphaMissense 0.25
- A36D (p.Ala36Asp), rs758917151, gnomAD 14-20344992-C-A, REVEL 0.05, CADD 14.80
- K38R (p.Lys38Arg), gnomAD 14-20344998-A-G, REVEL 0.05, AlphaMissense 0.21
- T39A (p.Thr39Ala), gnomAD 14-20345000-A-G, REVEL 0.04, AlphaMissense 0.11
- T39I (p.Thr39Ile), gnomAD 14-20345001-C-T, REVEL 0.03, AlphaMissense 0.18
- R40C (p.Arg40Cys), rs780728837, gnomAD 14-20345003-C-T, REVEL 0.06, CADD 17.90
- R40G (p.Arg40Gly), rs780728837, gnomAD 14-20345003-C-G, REVEL 0.07, CADD 15.80
- R40L (p.Arg40Leu), gnomAD 14-20345004-G-T, REVEL 0.03, CADD 9.78
- R40H (p.Arg40His), rs747294136, gnomAD 14-20345004-G-A, REVEL 0.07, CADD 15.20
- R40R (p.Arg40Arg), rs755409276, gnomAD 14-20345005-T-G, CADD 2.82
- R41K (p.Arg41Lys), gnomAD 14-20345007-G-A, REVEL 0.04, CADD 9.02
- R41T (p.Arg41Thr), gnomAD 14-20345007-G-C, REVEL 0.02, CADD 10.10
- R41S (p.Arg41Ser), rs777279053, gnomAD 14-20345008-A-T, REVEL 0.03, CADD 15.40
- C42S (p.Cys42Ser), rs1435242860, gnomAD 14-20345009-T-A, REVEL 0.05, CADD 12.90
- C42Y (p.Cys42Tyr), rs749038617, gnomAD 14-20345010-G-A, REVEL 0.05, CADD 15.10
- C42C (p.Cys42Cys), rs939195785, gnomAD 14-20345011-C-T, CADD 7.34
- Q43H (p.Gln43His), NCI-TCGA Cosmic COSV9916, cosmic curated COSV99163, Variant assessed as somatic; moderate impact.
- Q43* (p.Gln43Ter), gnomAD 14-20345012-C-T, CADD 33.00
- Q43E (p.Gln43Glu), rs1883658966, gnomAD 14-20345012-C-G, REVEL 0.07, CADD 6.70
- Q43R (p.Gln43Arg), rs1883659127, gnomAD 14-20345013-A-G, REVEL 0.08, CADD 12.10
- Q43Q (p.Gln43Gln), rs770574488, gnomAD 14-20345014-G-A, CADD 5.74
- R44G (p.Arg44Gly), rs1433531281, gnomAD 14-20345015-A-G, REVEL 0.11, CADD 22.50
- Q45R (p.Gln45Arg), gnomAD 14-20345019-A-G, REVEL 0.04, CADD 11.80
- E46K (p.Glu46Lys), rs773793994, gnomAD 14-20345021-G-A, REVEL 0.04, CADD 3.94
- E46D (p.Glu46Asp), rs935283796, gnomAD 14-20345023-G-C, REVEL 0.03, AlphaMissense 0.44
- S47* (p.Ser47Ter), gnomAD 14-20345025-C-A, CADD 27.00
- S47L (p.Ser47Leu), gnomAD 14-20345025-C-T, REVEL 0.09, CADD 2.31
- S47W (p.Ser47Trp), gnomAD 14-20345025-C-G, REVEL 0.08, CADD 10.60
- S47S (p.Ser47Ser), rs1883659945, gnomAD 14-20345026-G-A, CADD 1.47
- K48N (p.Lys48Asn), NCI-TCGA Cosmic COSV5163, cosmic curated COSV51638, Variant assessed as somatic; moderate impact.
- K48T (p.Lys48Thr), rs1244487469, gnomAD 14-20345028-A-C, REVEL 0.10, CADD 18.50
- K48I (p.Lys48Ile), rs1244487469, gnomAD 14-20345028-A-T, REVEL 0.10, CADD 22.80
- K49R (p.Lys49Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K49N (p.Lys49Asn), gnomAD 14-20345032-G-C, REVEL 0.02, CADD 9.43
- M50V (p.Met50Val), rs527404505, gnomAD 14-20345033-A-G, REVEL 0.03, AlphaMissense 0.13
- P51S (p.Pro51Ser), NCI-TCGA TCGA novel, REVEL 0.06, CADD 11.80, Variant assessed as somatic; moderate impact.
- P51A (p.Pro51Ala), rs915323395, gnomAD 14-20345036-C-G, REVEL 0.06, CADD 4.11
- P51T (p.Pro51Thr), gnomAD 14-20345036-C-A, REVEL 0.06, CADD 10.20
- P51P (p.Pro51Pro), gnomAD 14-20345038-T-C, CADD 5.14
- V52E (p.Val52Glu), rs1209544076, gnomAD 14-20345040-T-A, REVEL 0.07, AlphaMissense 0.59
- V52V (p.Val52Val), rs1490324847, gnomAD 14-20345041-G-A, CADD 3.10
- A53V (p.Ala53Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G54R (p.Gly54Arg), gnomAD 14-20345045-G-A, REVEL 0.03, AlphaMissense 0.14
- G54G (p.Gly54Gly), rs771962024, gnomAD 14-20345047-A-G, CADD 8.51
- G55R (p.Gly55Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G55E (p.Gly55Glu), gnomAD 14-20345049-G-A, REVEL 0.05, CADD 7.74
- G55G (p.Gly55Gly), rs775539840, gnomAD 14-20345050-A-G, CADD 6.21
- K56E (p.Lys56Glu), rs760368901, gnomAD 14-20345051-A-G, REVEL 0.01, CADD 4.18
- K56N (p.Lys56Asn), rs764004387, gnomAD 14-20345053-A-T, REVEL 0.03, CADD 7.31
- A57P (p.Ala57Pro), rs1883661724, gnomAD 14-20345054-G-C, REVEL 0.01, CADD 1.78
- A57T (p.Ala57Thr), gnomAD 14-20345054-G-A, REVEL 0.01, CADD 0.87
- N58I (p.Asn58Ile), rs1267393159, gnomAD 14-20345056-TA-T, CADD 19.20
- N58H (p.Asn58His), gnomAD 14-20345057-A-C, REVEL 0.03, CADD 9.94
- N58S (p.Asn58Ser), rs1423083780, gnomAD 14-20345058-A-G, REVEL 0.02, CADD 7.66
- N58T (p.Asn58Thr), gnomAD 14-20345058-A-C, REVEL 0.02, CADD 8.00
- N58N (p.Asn58Asn), rs776710514, gnomAD 14-20345059-T-C, CADD 2.34
- K59E (p.Lys59Glu), rs762055576, gnomAD 14-20345060-A-G, REVEL 0.00, AlphaMissense 0.07
- K59N (p.Lys59Asn), gnomAD 14-20345062-G-C, REVEL 0.01, CADD 7.23
- D60G (p.Asp60Gly), gnomAD 14-20345064-A-G, REVEL 0.02, CADD 15.90
- D60D (p.Asp60Asp), rs1444809168, gnomAD 14-20345065-C-T, CADD 5.77
- R61G (p.Arg61Gly), rs1056533791, gnomAD 14-20345066-A-G, REVEL 0.03, CADD 13.40
- R61K (p.Arg61Lys), gnomAD 14-20345067-G-A, REVEL 0.04, CADD 10.60
- R61R (p.Arg61Arg), gnomAD 14-20345068-G-A, CADD 7.77
- T62A (p.Thr62Ala), gnomAD 14-20345069-A-G, REVEL 0.11, CADD 21.10
- T62K (p.Thr62Lys), rs1157867617, gnomAD 14-20345070-C-A, REVEL 0.03, CADD 15.10
- E63Q (p.Glu63Gln), rs202077893, gnomAD 14-20345072-G-C, REVEL 0.03, CADD 18.00
- D64N (p.Asp64Asn), rs758579659, gnomAD 14-20345075-G-A, REVEL 0.02, CADD 18.80
- K65* (p.Lys65Ter), rs1305159041, gnomAD 14-20345078-A-T, CADD 35.00
- K65K (p.Lys65Lys), rs1883663600, gnomAD 14-20345080-G-A, CADD 8.82
- Q66R (p.Gln66Arg), rs766961437, gnomAD 14-20345082-A-G, REVEL 0.03, CADD 18.90
- G68D (p.Gly68Asp), NCI-TCGA Cosmic COSV5164, cosmic curated COSV51642, Variant assessed as somatic; moderate impact.
- M69V (p.Met69Val), rs1395916606, gnomAD 14-20345090-A-G, CADD 5.51
- P70S (p.Pro70Ser), gnomAD 14-20345429-C-T, REVEL 0.20, CADD 25.20
- P70A (p.Pro70Ala), rs746511446, gnomAD 14-20345429-C-G, REVEL 0.13, CADD 21.60
- P70L (p.Pro70Leu), rs1883680140, gnomAD 14-20345430-C-T, REVEL 0.22, CADD 27.50
- P70P (p.Pro70Pro), rs768585646, gnomAD 14-20345431-T-C, CADD 6.24
- G71R (p.Gly71Arg), gnomAD 14-20345096-G-A, CADD 0.99
- G71A (p.Gly71Ala), gnomAD 14-20345097-G-C, CADD 0.88
- G71S (p.Gly71Ser), rs200569736, gnomAD 14-20345420-G-A, REVEL 0.32, CADD 26.30
- R72K (p.Arg72Lys), rs2501879079, ClinGen CA389117705, ClinVar RCV004167010, Uncertain significance, not specified
- p.Arg72dup, gnomAD 14-20345096-G-GGA, CADD 2.57
- R72G (p.Arg72Gly), rs372717118, gnomAD 14-20345099-A-G, CADD 14.90
- R72S (p.Arg72Ser), gnomAD 14-20345101-G-T, CADD 5.04
Public PARP2 analysis runs
- PARP2 analysis run — PARP2 (352 variants) — completed 2026-08-22